Teladoc Health (NYSE: TDOC) and InMode (NASDAQ: INMD) both operate in high-growth industries. Teladoc is a leader in telemedicine. InMode specializes in selling devices in the minimally invasive and non-invasive aesthetics market. Both of these areas are delivering double-digit growth. And this equals big opportunity for these innovative companies.

Teladoc and InMode may offer investors a buying opportunity when it comes to price, too. They have fallen quite a bit from their record highs -- and are trading below analysts' 12-month share price forecasts. Now the question is: How much opportunity for gains lies ahead? And which of these players is more likely to rise fivefold first?

First, a bit about what's weighed on Teladoc shares. Teladoc has delivered quarter after quarter of double-digit revenue increases (and even triple-digit growth during the earlier stages of the pandemic). Still, investors have worried about the company's ability to turn rising revenue into a profit one day. And the company's billions of dollars in non-cash goodwill impairment charges last year deepened concerns. The charges were linked to a 2020 acquisition.

Continue reading

Source Fool.com